Hydroxyethyl starch and coagulation

[1]  P. Collins,et al.  Hydroxyethyl starch induced acquired von Willebrand's disease. , 2008, Clinical and laboratory haematology.

[2]  J. Treib,et al.  Coagulation Disorders Caused by Hydroxyethyl Starch , 1997, Thrombosis and Haemostasis.

[3]  K. Schimrigk,et al.  Avoiding an impairment of factor VIII:C by using hydroxyethyl starch with a low in vivo molecular weight. , 1997, Anesthesia and analgesia.

[4]  S. Reeves,et al.  The Effects of Desmopressin and 6% Hydroxyethyl Starch on Factor VIII: C , 1996, Anesthesia and analgesia.

[5]  K. Schimrigk,et al.  Influence of low molecular weight hydroxyethyl starch (HES 40/0.5-0.55) on hemostasis and hemorheology. , 1996, Haemostasis.

[6]  K. Schimrigk,et al.  Highly substituted hydroxyethyl starch (HES200/0.62) leads to Type-I von Willebrand syndrome after repeated administration. , 1996, Haemostasis.

[7]  K. Schimrigk,et al.  All medium starches are not the same: Influence of the degree of hydroxyethyl substitution of hydroxyethyl starch on plasma volume, hemorrheologic conditions, and coagulation , 1996, Transfusion.

[8]  K. Schimrigk,et al.  HES 200/0.5 Is not HES 200/0.5 , 1995, Thrombosis and Haemostasis.

[9]  K. Mori,et al.  Hemorheological and hemodynamic analysis of hypervolemic hemodilution therapy for cerebral vasospasm after aneurysmal subarachnoid hemorrhage. , 1995, Stroke.

[10]  Z. Ruggeri.  Pathogenesis and classification of von Willebrand disease. , 1994, Haemostasis.

[11]  J. C. Chang,et al.  Disseminated intravascular coagulation due to intravenous administration of hetastarch. , 1990, The American journal of the medical sciences.

[12]  P. Zangger,et al.  Adjusted hypervolemic hemodilution in acute ischemic stroke. , 1990, Stroke.

[13]  J. Triedman,et al.  A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. , 1989, The Journal of thoracic and cardiovascular surgery.

[14]  L. Wilkins.  Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. The Hemodilution in Stroke Study Group. , 1989, Stroke.

[15]  L. Wilkins.  Multicenter trial of hemodilution in acute ischemic stroke. Results of subgroup analyses. Scandinavian Stroke Study Group. , 1988, Stroke.

[16]  Suberviola Pd,et al.  Development of a von Willebrand-like syndrome after prolonged use of hydroxyethyl starch. , 1987 .

[17]  R. Stricker,et al.  Intracranial bleeding during treatment with hydroxyethyl starch. , 1987, The New England journal of medicine.

[18]  L. Wilkins.  Multicenter trial of hemodilution in acute ischemic stroke. I. Results in the total patient population. Scandinavian Stroke Study Group. , 1987 .

[19]  R. Wilson,et al.  Dangers of using an improvised underwater seal for CPAP oxygenation during one-lung ventilation. , 1987, Anesthesiology.

[20]  G. Silverberg,et al.  Hetastarch coagulopathy in a neurosurgical patient. , 1987, Anesthesiology.

[21]  Symington Be.  Hetastarch and bleeding complications. , 1986 .

[22]  K. Korttila,et al.  Effect of Hydroxyethyl Starch and Dextran on Plasma Volume and Blood Hemostasis and Coagulation , 1984, Journal of clinical pharmacology.

[23]  H. Zschiedrich,et al.  [The effects of 500 ml 10% hydroxyethyl starch 200/0.5 and 10% dextran 40 on blood volume, colloid osmotic pressure and renal function in human volunteers (author's transl)]. , 1982, Der Anaesthesist.

[24]  C. R. Ricketts,et al.  Post-transfusion survival of hydroxyethyl starch 450/0·70 in man: a long-term study , 1980, Journal of clinical pathology.

[25]  Z. Ruggeri,et al.  Von Willebrand's disease. , 1976, British medical journal.

[26]  H. Bergmann,et al.  [The influence of hydroxyethyl starch on postoperative alterations of blood coagulation (author's transl)]. , 1975, Der Anaesthesist.

[27]  K. Peter,et al.  [The influence of hydroxyethyl starch on blood clotting (author's transl)]. , 1975, Der Anaesthesist.

[28]  S. Chakrabarti.  Studies on hydroxyethyl starch , 1973 .

[29]  J. Treib,et al.  Effect of hydroxyethyl starch on coagulation is difficult to assess in vitro. , 1998, British journal of anaesthesia.

[30]  K. Schimrigk,et al.  Increased haemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch. , 1997, Arzneimittel-Forschung.

[31]  J. Treib,et al.  HETASTARCH COAGULOPATHY. AUTHOR'S REPLY , 1996 .

[32]  S. Choi,et al.  Coagulopathy with the use of hetastarch in the treatment of vasospasm. , 1995, Journal of neurosurgery.

[33]  R. Dauman,et al.  [Value of the association of normovolemic dilution and hyperbaric oxygenation in the treatment of sudden deafness. A retrospective study]. , 1993, Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Societe d'oto-laryngologie des hopitaux de Paris.

[34]  J. Treib,et al.  Hemodilution in Cerebral Circulatory Disturbances: Indications, Implementation, Additional Drug Treatment, and Alternatives , 1992 .

[35]  M. Reim,et al.  [Hemodilution in acute arterial circulatory disorders of the retina]. , 1991, Acta medica Austriaca.

[36]  K. Asplund.  Hemodilution in Acute Stroke , 1991 .

[37]  K. Asplund,et al.  Multicenter trial of hemodilution in acute ischemic stroke. I. Results in the total patient population. Scandinavian Stroke Study Group. , 1987, Stroke.

[38]  K. Lechner,et al.  Vier Fälle mit erworbenem von Willebrand-Syndrom und monoklonaler Gammopathie. Langzeitverlauf sowie diagnostische und therapeutische Problematik , 1987 .

[39]  H. Förster,et al.  Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers. , 1985, Arzneimittel-Forschung.